Business Standard

The Association of India (MTaI), a body representing leading companies, Monday said the increase in coronary prices is in line with and in the interest of the industry.

The organisation, in a statement, said the hike is testimony to government’s commitment to quality in the country.

“The increase in prices of stents indicates that the (NPPA) is mindful of the operational pressures in the medical device industry,” MTaI said in the statement.

He expressed hope that in the interest of Indian patients, the government will bring in a policy to differentially price the innovative generations of

“We are also engaged with the NPPA to find a way to offset the exchange value depreciation and thus mitigate the economic threats in the system to the medical device industry,” Choudary said.

Drug price regulator NPPA has approved hike in prices of cardiac stents by 4.2 per cent in-line with the wholesale price index (WPI) of the previous calendar year, as per an official statement.

As per the new prices notified by the NPPA, a bare metal (BMS) would now cost Rs 8,261, while the drug eluting (DES) will cost Rs 30,080 from April 1.

A is a tube-shaped device placed in the arteries that supplies blood to heart. It keeps the arteries open in the